Immunity status

Characteristics of MTX therapy

Number of therapies

Duration (months)^†

Accumulated dose (mg)^†

HBcAb-positive(n = 14)

13

32.8 ± 46.8

2647.9 ± 2183.1

HBcAb-negative (n = 47)

46

27.1 ± 33.7

2149.4 ± 2534.0

P value

0.704^‡

<0.8^§

<0.5^§